Envoy Medical Seeks Shareholder Nod for Warrant Issuance, Dilution Looms

TL;DR

**Vote FOR the warrant issuance, but brace for dilution as Envoy Medical needs this capital to stay competitive and fund operations.**

AI Summary

Envoy Medical, Inc. (COCHW) is seeking stockholder approval for the issuance of warrants to purchase up to 5,725,206 shares of Class A Common Stock and an additional 143,130 shares (plus 7.5% of exercised Private Warrants) in placement agent warrants, as required by Nasdaq Listing Rule 5635(d). This approval relates to a securities purchase agreement dated September 22, 2025, with accredited and institutional investors, and an engagement letter with H.C. Wainwright & Co., LLC from September 17, 2025. The Private Warrants have an exercise price of $1.31 per share and expire 24 months after stockholder approval, while Placement Agent Warrants have an exercise price of $1.6375 per share. The company conducted a Registered Offering of 1,908,402 shares at $1.31 per share and a Private Placement of the Private Warrants, which closed on September 23, 2025. The Board of Directors recommends a 'FOR' vote on both the Issuance Proposal and the Adjournment Proposal at the Special Meeting on November 26, 2025. Failure to approve the Issuance Proposal would prevent the exercisability of these warrants, potentially impacting future capital raising and the company's financial flexibility. The issuance of these warrants will result in dilution for existing stockholders.

Why It Matters

This DEF 14A filing is crucial for Envoy Medical investors as it directly impacts the company's capital structure and potential for future dilution. Approval of the Issuance Proposal will allow the exercise of warrants for up to 5,725,206 shares, significantly increasing the outstanding share count and diluting existing shareholders' percentage ownership. For employees and customers, successful capital raises can signal stability and investment in product development, but the terms of this financing suggest a need for capital that could reflect underlying business challenges. In the competitive medical device market, the ability to raise capital is vital for innovation and market share, and this move indicates Envoy Medical is actively seeking to strengthen its financial position, potentially at the cost of immediate shareholder value.

Risk Assessment

Risk Level: medium — The risk level is medium because while the company is seeking to raise capital, the issuance of warrants for up to 5,725,206 shares of Class A Common Stock, plus additional Placement Agent Warrants, will result in significant dilution for existing stockholders. This dilution, coupled with the need for stockholder approval under Nasdaq Listing Rule 5635(d), suggests the company is navigating a critical financing event that could impact its stock price and long-term shareholder value.

Analyst Insight

Investors should vote 'FOR' the Issuance Proposal to ensure Envoy Medical can access necessary capital, but be prepared for potential stock price volatility due to the impending dilution from warrant exercises. Evaluate the company's long-term growth prospects and how this capital infusion will be utilized to offset the dilutive effect.

Key Numbers

• 5,725,206 — Private Warrants Shares (Number of Class A Common Stock shares underlying Private Warrants, representing potential dilution.)
• 143,130 — Placement Agent Warrants Shares (Initial number of Class A Common Stock shares underlying Placement Agent Warrants, contributing to dilution.)
• $1.31 — Private Warrant Exercise Price (Exercise price per share for Private Warrants, indicating the price at which new shares can be issued.)
• $1.6375 — Placement Agent Warrant Exercise Price (Exercise price per share for Placement Agent Warrants.)
• 23,809,975 — Shares Outstanding (Total Class A Common Stock shares outstanding as of October 2, 2025, against which dilution will be measured.)
• September 22, 2025 — Securities Purchase Agreement Date (Date of the agreement leading to the warrant issuance.)
• September 23, 2025 — Private Placement Closing Date (Date the Private Placement of warrants closed.)
• November 26, 2025 — Special Meeting Date (Date stockholders will vote on the Issuance Proposal.)
• 7.5% — Placement Agent Warrant Percentage (Percentage of exercised Private Warrants that will generate additional Placement Agent Warrants.)
• 24 months — Private Warrant Expiration (Duration Private Warrants are exercisable following stockholder approval.)

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant seeking stockholder approval
• Nasdaq Listing Rule 5635(d) (regulator) — Rule requiring stockholder approval for warrant issuance
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for the Private Placement
• Brent Lucas (person) — Chief Executive Officer, Director of Envoy Medical, Inc.
• $0.0001 (dollar_amount) — Par value per share of Class A Common Stock
• $1.31 (dollar_amount) — Purchase price per share in Registered Offering and Private Warrant exercise price
• $1.6375 (dollar_amount) — Exercise price per share for Placement Agent Warrants
• 5,725,206 (dollar_amount) — Aggregate number of shares purchasable via Private Warrants
• 143,130 (dollar_amount) — Number of shares purchasable via initial Placement Agent Warrants
• 23,809,975 (dollar_amount) — Shares of Class A Common Stock outstanding as of October 2, 2025

FAQ

Risk Factors

• Dilution from Warrant Issuance [medium — financial]: The company is seeking approval to issue warrants to purchase up to 5,725,206 shares of Class A Common Stock, plus additional placement agent warrants. This issuance, required by Nasdaq Listing Rule 5635(d), will result in significant dilution to existing stockholders. The private warrants have an exercise price of $1.31 and expire in 24 months, while placement agent warrants have an exercise price of $1.6375.
• Nasdaq Listing Rule Compliance [high — regulatory]: The primary purpose of the Special Meeting is to obtain stockholder approval for the issuance of warrants to comply with Nasdaq Listing Rule 5635(d). Failure to secure this approval would prevent the warrants from being exercisable, impacting the company's ability to raise future capital and maintain its Nasdaq listing.

Industry Context

Envoy Medical operates in the medical device sector, specifically focusing on implantable hearing solutions. The industry is characterized by significant research and development costs, regulatory hurdles from bodies like the FDA, and a competitive landscape with established players and emerging technologies. Companies in this space often rely on capital raises to fund clinical trials, product development, and market expansion.

Regulatory Implications

Compliance with Nasdaq Listing Rules is a critical regulatory aspect for Envoy Medical, as highlighted by the need for shareholder approval under Rule 5635(d). Failure to meet these requirements could jeopardize the company's listing status. Additionally, as a medical device company, Envoy Medical is subject to stringent FDA regulations regarding product safety and efficacy, which can impact development timelines and market access.

What Investors Should Do

1. Vote FOR the Issuance Proposal
2. Vote FOR the Adjournment Proposal
3. Review the potential dilution

Key Dates

• 2025-09-17: Engagement Letter with H.C. Wainwright & Co., LLC — This engagement letter outlines the terms under which H.C. Wainwright & Co. will act as placement agent, leading to the issuance of placement agent warrants.
• 2025-09-22: Securities Purchase Agreement Date — This agreement details the terms of the private placement of warrants with accredited and institutional investors.
• 2025-09-23: Private Placement Closing Date — The date on which the private placement of warrants was completed.
• 2025-10-02: Record Date for Special Meeting — Stockholders of record on this date are entitled to vote at the Special Meeting.
• 2025-10-17: Mailing of Notice of Internet Availability of Proxy Materials — Informs stockholders about the upcoming meeting and how to access proxy materials.
• 2025-11-26: Special Meeting Date — The date stockholders will vote on the Issuance Proposal and Adjournment Proposal.

Glossary

DEF 14A

A filing with the SEC that provides detailed information to shareholders when the company is soliciting proxies for its annual or special meetings. (This document is the proxy statement for Envoy Medical's special meeting, outlining the proposals for shareholder vote.)

Class A Common Stock

The common stock of Envoy Medical, with a par value of $0.0001 per share. Holders of this stock are entitled to vote at the special meeting. (The underlying shares for the warrants being issued, and the stock held by voting shareholders.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase shares of the company's stock at a specified price (exercise price) within a specified period (expiration date). (Envoy Medical is seeking approval to issue these warrants, which will lead to potential dilution and capital raising.)

Private Warrants

Warrants issued in a private placement, typically to accredited or institutional investors, and not registered for public sale. (These are a significant portion of the warrants being issued, with an exercise price of $1.31 and a 24-month expiration.)

Placement Agent Warrants

Warrants issued to the placement agent (H.C. Wainwright & Co.) as compensation for their services in facilitating the securities offering. (These warrants have a higher exercise price of $1.6375 and are partly based on the exercise of private warrants.)

Nasdaq Listing Rule 5635(d)

A rule requiring shareholder approval for the issuance of securities in connection with certain private placements when the issuance involves a change of control, a sale of substantially all assets, or when the issuance price is below the Minimum Price (as defined by the rule). (Envoy Medical needs shareholder approval under this rule to issue the warrants, as the issuance price might be considered below market or for other reasons requiring such approval.)

Dilution

The reduction in the ownership percentage of existing shareholders when a company issues new shares or securities that are convertible into shares. (The issuance of up to 5,725,206 shares underlying the warrants will dilute the ownership stake of current stockholders.)

Proxy Statement

A document filed with the SEC that provides shareholders with information about matters to be voted on at a shareholder meeting. (This document is the proxy statement for Envoy Medical's special meeting, detailing the proposals and providing information for shareholders to make informed voting decisions.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting and does not contain comparative financial data from a previous annual report. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks to a prior period is not possible based solely on this document. The focus is on the upcoming vote regarding warrant issuance and its implications.

Key Financial Figures

• $0.0001 — Class A Common Stock, par value $0.0001 (“Class A Common Stock&#x
• $1.31 — Stock”), at a purchase price of $1.31 per share; and (ii) in a private
• $1 — tock) at an exercise price per share of $1.6375, which will be exercisable commenc
• $1.6375 — ve initial exercise prices of $1.31 and $1.6375 per share, respectively. Accordingly, w
• $8.4 — ize an aggregate of up to approximately $8.4 million in gross proceeds if all

Filing Documents

• ea0260470-02.htm (DEF 14A) — 197KB
• tproxy_001.jpg (GRAPHIC) — 510KB
• tproxy_002.jpg (GRAPHIC) — 594KB
• 0001213900-25-099960.txt ( ) — 1719KB

From the Filing

DEF 14A 1 ea0260470-02.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ SCHEDULE 14A __________________________________________ Proxy Statement Pursuant to Section 14(a) (Rule 14a-101) of the Securities Exchange Act of 1934 Filed by the Registrant   Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2))   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material Pursuant to §240.14a -12 Envoy Medical, Inc. (Name of Registrant as Specified in its Charter) _________________________________________________________________ (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box):   No fee required.   Fee paid previously with preliminary materials.   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11 .   PRELIMINARY MATERIALS Envoy Medical, INC. 4875 White Bear Parkway White Bear Lake, MN 55110 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON November 26, 2025 TO THE STOCKHOLDERS OF Envoy Medical, INC.: Please Take Notice that Envoy Medical, Inc. (“Envoy Medical” or the “Company”) will hold a Special Meeting of Stockholders at 4875 White Bear Parkway White Bear Lake, MN 55110 on November 26, 2025 at 9:00 a.m. local time. Envoy Medical is holding this meeting for the purpose of considering and taking appropriate action with respect to the following: 1.        To approve, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Company’s Class A Common Stock, par value $0.0001 (“Class A Common Stock”), and the issuance of Class A Common Stock underlying such warrants, pursuant to the terms of that certain securities purchase agreement by and among the Company and certain purchasers named therein, dated as of September 22, 2025, and that certain engagement letter by and between the Company and H.C. Wainwright & Co., LLC, dated as of September 17, 2025 (the “Issuance Proposal”); 2.        To approve one or more adjournments of the Special Meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event there are not sufficient votes in favor of the Issuance Proposal or to constitute a quorum, as described in this proxy statement (the “Adjournment Proposal”); and 3.        To transact any other business as may properly come before the meeting or any adjournments thereof, including matters incident to the conduct of the Special Meeting. Holders of record of Envoy Medical Class A Common Stock at the close of business on October 2, 2025 will be entitled to vote at the meeting or any adjournments thereof. Your attention is directed to the Proxy Statement accompanying this Notice for a more complete statement of the matters to be considered at the meeting.   By Order of the Board of Directors,     /s/ Brent Lucas Date: October 17, 2025   Chief Executive Officer, Director Your vote is important. To vote your shares, please vote by telephone or Internet, as directed in the Proxy Statement, or if you received a proxy card or voting instruction form by mail, please complete, sign, date and mail the proxy card or voting instruction form promptly in the envelope provided. The prompt return of proxies will save Envoy Medical the expense of further requests for proxies. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 26, 2025: This Notice and the Proxy Statement are available at www.iproxydirect.com / coch and on the Investor Relations section of Envoy Medical’s website at ir.envoymedical.com .   Envoy Medical, INC. 4875 White Bear Parkway White Bear Lake, MN 55110 PROXY STATEMENT SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON November 26, 2025 This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of Envoy Medical, Inc., a Delaware corporation (“Envoy Medical,” the “Company,” “we,” “our” or “us”), for use at the Special Meeting of Stockholders (the “Special Meeting”) to be held at 4875 White Bear Parkway White Bear Lake, MN 55

View Full Filing

View this DEF 14A filing on SEC EDGAR